Viridian Therapeutics, Inc.\DE Annual Operating Income (Loss) in USD from 2013 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Viridian Therapeutics, Inc.\DE quarterly/annual Operating Income (Loss) history and growth rate from 2013 to 2023.
  • Viridian Therapeutics, Inc.\DE Operating Income (Loss) for the quarter ending September 30, 2024 was -$83.5M, a 63% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE Operating Income (Loss) for the twelve months ending September 30, 2024 was -$283M, a 22% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Operating Income (Loss) for 2023 was -$254M, a 89.5% decline from 2022.
  • Viridian Therapeutics, Inc.\DE annual Operating Income (Loss) for 2022 was -$134M, a 68.5% decline from 2021.
  • Viridian Therapeutics, Inc.\DE annual Operating Income (Loss) for 2021 was -$79.7M, a 27.8% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.